JAK2 and essential thrombocythemia: Similarly, the mutation rate of V617F and other mutations in ET was 44.4% (12/27), while the adjusted mutation rate was 53.1% (17/32), as five patients with clinically suspected ET were added to the ET group following JAK2 testing.